Branchen
Biopharmaceuticals & Rare Diseases
Alle Analysen in Biopharmaceuticals & Rare Diseases — 3 Analysen.
38/100
Rocket Pharmaceuticals: Cash Buys Time, but Danon Still Has to Earn Back the Market's Trust
Rocket Pharmaceuticals (RCKT.US) is a rare-disease gene-therapy developer whose sole approved product, Kresladi, still generates no revenue, leaving cash and a $180 million voucher sale as the real near-term story. The stock trades near the value of its cash alone because the market still distrusts the pivotal Danon cardiac program after a 2025 clinical hold, even though Phase 1 data and a modified lower-dose cohort keep the thesis alive. Rating Hold: cash buys time, but Danon still has to earn back trust and Kresladi is too small to carry the valuation on its own.
45/100
BioMarin Pharmaceutical: A Rare-Disease Cash Engine in Transition
BioMarin is a profitable rare-disease biopharma whose enzyme franchise generated about 2.106 billion USD of 2025 revenue and funds the company, while VOXZOGO (926.9 million USD) drives both growth and sentiment. The Amicus acquisition diversified the portfolio into Fabry and Pompe disease and lifted 2026 revenue guidance to 3.825-3.925 billion USD, yet weekly and oral achondroplasia rivals from Ascendis and BridgeBio keep the margin of safety thin. Rating Hold: cash generation and Amicus diversification make BioMarin sturdier than sentiment implies, but VOXZOGO competition caps the upside at today's price.
55/100
38Buffett
argenx (ARGX.US / ARGX.BR): Ein Zen Horizon Bericht
argenx ist der globale Marktführer bei Antikörpertherapien für seltene Autoimmunerkrankungen und der First-in-Class-Pionier des Feldes der FcRn-Inhibitoren. Das Kernprodukt Vyvgart (Efgartigimod) ist inzwischen in drei Indikationen zugelassen (gMG und CIDP global sowie ITP in Japan), mit rund 19000 Patienten in Therapie, einem Nettoumsatz von USD 4.15 Milliarden im GJ2025 (+90%) und einem erstmals positiven Betriebsergebnis von USD 1.05 Milliarden. Vision 2030 zielt auf 50000 Patienten, 10 Zulassungen und 5 Moleküle in Phase III. Rating Beobachten: ein wirklich starkes Asset, dessen Kurs von USD 882.41 eine reibungslose Umsetzung bereits einpreist, sodass sich das Einstiegsfenster erst bei einem Rückgang auf USD 720 oder darunter öffnet.